Skip to main content
Mark Thompson, MD, Oncology, Blacklick, OH


Oncology Blacklick, OH

Breast Cancer, Hematologic Oncology

The Mark H. Zangmeister Cancer Center

Dr. Thompson is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Thompson's full profile

Already have an account?

Education & Training

  • University of Kentucky College of Medicine
    University of Kentucky College of MedicineFellowship, Hematology, 1984 - 1986
  • Mount Carmel Medical CenterResidency, Internal Medicine, 1981 - 1984
  • Wright State University
    Wright State UniversityClass of 1981
  • Ohio State University
    Ohio State UniversityB.A., 1972 - 1975
  • Ohio Wesleyan UniversityNo Degree, 1970 - 1972

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1982 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Alpha Omega Alpha Honor Society

Publications & Presentations

Journal Articles

  • Policy prescriptions to fix our ailing delivery system  
    Brow M, Okon T, Books B, Thompson M, Community Oncology, 12/1/2013
  • Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer  
    Puhalla S, Mrozek E, Young D, Ottman S, McVey A, Kendra K, Merriman N, Knapp M, Patel T, Thompson ME, Maher JF, Moore TD, Shapiro CL, J Clin Oncol, 1/1/2008
  • Marked Hypoloidy in Blast Phase Chronic Myelogenous Leukemia: Report of a Case and Review of the Literature  
    Cibull M, Thompson M, Smith L, Jennings CD, Doukas M, Pavlik E, Powell D, American Journal of Hematology, 1/1/1987

Books/Book Chapters


  • A single pegfilgrastim dose per cycle supports dose-dosedense (q14d) CHOP-R in patients with Non-Hodgkin's Lymphoma.
    Moore TD, Patel T, Segal ML, Zangmeister J, Chidiac TA, Roach RW, Thompson ME, Merriman N, Larrimer NR, Maher J, Christensen R, Ashbury FD, American Society of Hematology, San Diego, CA, 12/7/2003
  • Integration of clinical trial decision rules in an electronic medical record (EMR) enhances patient accrual and facilitates data management, quality control and analysis.
    Moore TD, Hotz K, Christensen R, Litwak D, Meyer J, Baxter T, Thompson M, Ashbury FD, Proc Am Soc Clin Oncol, 1/1/2003
  • A Single Pegfilgrastim Dose Per Cycle Supports Dose-Dense (q14d) CHOP-R in Patients with NHL.
    Moore T, Patel T, Segal M, Zangmeister J, Chidiac T, Roach R, Thompson M, Larrimer N, Journal of American Society of Hematology-Blood, 11/16/2002
  • Join now to see all

Press Mentions

  • Community Oncology Alliance Releases Six New Position Statements
    Community Oncology Alliance Releases Six New Position StatementsSeptember 18th, 2019
  • Leading Radiation Oncologist, Mark Thompson, MD, Is to Be Recognized as a 2017 Top Doctor in Kansas City, Missouri
    Leading Radiation Oncologist, Mark Thompson, MD, Is to Be Recognized as a 2017 Top Doctor in Kansas City, MissouriJune 20th, 2017

Professional Memberships